They don't have enough supply yet for this incentive to be in effect. Once they reach the tipping point, look forward to them changing their tune. The good news is that it might actually align with the public's best interest.
Pfizer is going to be making 5.7 billion dollars in revenue from Paxlovid at the bare minimum in the next 6 months, in the US. That's around as much revenue as 300 million vaccine doses. We are already past the tipping point, as of around 20 days ago.
